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OBJECTIVE — Performance measures are tools for assessing quality of care but may be
inﬂuencedbypatientfactors.Weinvestigatedhowcurrentlyendorsedperformancemeasuresfor
glycemic control in diabetes may be inﬂuenced by case mix composition. We assessed differ-
ences in A1C performance measure threshold attainment by case mix factors for A1C 9% and
examined how lowering the threshold to A1C 8% or 7% changed these differences.
RESEARCH DESIGN AND METHODS — Using data from the 1999–2002 National
Health and Nutrition Examination Survey for 843 adults self-reporting diabetes, we computed
the mean difference in A1C threshold attainment of 9, 8, and 7% by various case mix
factors. The mean difference is the average percentage point difference in threshold attainment
for population groups compared with that for the overall population.
RESULTS — Diabetes medication was the only factor for which the difference in threshold
attainment increased at lower thresholds, with mean differences of 5.7 percentage points at A1C
9% (reference), 10.1 percentage points at A1C 8% (P  0.05), and 14.1 percentage points
at A1C 7% (P  0.001).
CONCLUSIONS — As 87% of U.S. adults have A1C 9%, a performance measure thresh-
old of 9% will not drive major improvements in glycemic control. Lower thresholds do not
exacerbate differences in threshold attainment for most factors. Reporting by diabetes medica-
tion use may compensate for heterogeneous case mix when a performance measure threshold of
A1C 8% or lower is used.
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T
he implementation of performance
measurestoprovidepublicaccount-
ability and ﬁnancial incentive for
quality health care represents a major
shift in the approach to improving popu-
lation health within the U.S (1). The
movement to measure quality diabetes
care involves establishing standards re-
latedtoglycemiccontrol,eyeandfootex-
aminations, urine protein screening, and
management of lipids and blood pressure
(2). The performance measure threshold
for glycemic control has been controver-
sial. More stringent measures may en-
courage overzealous treatment of
individuals to which more general guide-
lines do not apply. Conversely, providers
may mistake less stringent performance
measures for guidelines that have been
carefully developed by a number of med-
ical organizations to assist physicians in
setting therapeutic targets for their pa-
tients (3).
The most commonly cited guidelines
are those of the American Diabetes Asso-
ciation (ADA), which state that although
certain patient groups (e.g., elderly pa-
tientsorthosewithcomorbidity)maynot
beneﬁt from stringent glycemic targets,
maintaining A1C 7% is a reasonable
goal for individuals with diabetes (4). Af-
ter decades in which less than half of
Americans reached the target of A1C
7% (5), national data have shown im-
proved glycemic control in those with di-
abetes with 56% achieving A1C 7% in
2003–2004 (6,7). Even before these im-
provements, some stakeholders ques-
tioned whether linking pay for
performance programs to a 9% thresh-
old would encourage adequate glycemic
control for individual patients or propel
declines in A1C at the national level (8).
With only 13% of Americans with diag-
nosed diabetes having a A1C of 9% in
2003–2004, a performance measure of
9% may have limited ability to drive
population-wide quality improvement.
In contrast to clinical practice guide-
lines for glycemic control, such as the
ADA guideline, which address goals for
individual patients, performance mea-
sures are designed to indicate overall
healthcarequalitydeliveredacrossapop-
ulation of patients (9). An A1C perfor-
mance measure for holding providers
accountable may foster improvement in
population-level glycemic control, al-
though experts debate how to deﬁne an
optimal measure of health care quality
(10,11). This debate has led to different
thresholds established by different orga-
nizations and used for different purposes.
The National Diabetes Quality Improve-
ment Alliance (NDQIA), a consortium of
stakeholders interested in diabetes care,
has established two categories of perfor-
mance measures. The ﬁrst category of
measuresisintendedforqualityimprove-
ment efforts within an organization and
describes A1C values across the range of
6.0 to 10.0%. The second set of mea-
sures is that to which providers and
health plans will be accountable for pub-
lic reporting and on which performance-
based reimbursements will be based. The
glycemic control performance measure
that the NDQIA recommends for public
reporting is A1C 9% to indicate poor
control (12). The NDQIA has a good con-
trol measure of A1C 7% under “active
consideration” but stated that “before
such a measure can be put forward, ap-
propriate means for considering case mix
must be speciﬁed.” The National Quality
Forum (NQF), whose mission is to im-
prove health care quality through na-
tional performance standards, has
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ing the A1C 9% threshold for public
reporting. In contrast, the National Com-
mittee for Quality Assurance adopted a
Health Plan Employer Data and Informa-
tion Set measure of A1C 7% for public
accountability(13).Thismeasurehasun-
dergone scrutiny (10,11) because not all
patients should achieve this goal. Clinical
guidelines state that individual goals are
tobetailoredaccordingtoage,lifeexpect-
ancy, comorbidity, risk of hypoglycemia,
and patient preferences (4).
Part of the challenge of implementing
an A1C performance measure is prevent-
ing unintended consequences, such as
penalizing physicians who treat low-
income patients or patients with medi-
cally complicated diabetes in whom A1C
may be more difﬁcult to control. In its
rationale for the 9% threshold, the
NDQIA stated that [performance] mea-
sures “must account for differences in in-
dividual patient conditions and
preferences.” This wording suggests that
the NDQIA is adopting a lenient thresh-
old to diminish differences in threshold
attainment that are due to heterogeneity
in case mix.
Differencesinglycemiccontrolacross
age,BMI,durationofdiabetes,anddiabe-
tes medication use (6,14) indicate that
these case mix factors are likely to inﬂu-
ence performance measure attainment.
Differences in glycemic control by race/
ethnicityhavealsobeenreported(15)but
may be a function of access to care (16).
Education and income level may inﬂu-
ence measures of diabetes care indepen-
dent of access to care (16). Determining
the effect of threshold choice on the mag-
nitudeofcasemixfactordifferencesisim-
portant for the careful selection of a
performance measure. Using representa-
tivedatafromindividualswithdiabetesin
the U.S. and considering A1C thresholds
of 9, 8, and 7%, we computed esti-
mates of differences in threshold attain-
ment for various patient factors and
determined how the magnitude of differ-
ences is affected by choice of threshold.
RESEARCH DESIGN AND
METHODS— Data for this cross-
sectional analysis come from the 1999–
2002 National Health and Nutrition
ExaminationSurvey(NHANES).Thison-
going survey conducted by the National
Center for Health Statistics uses a strati-
ﬁed, multistage, probability cluster de-
sign that results in a nationally
representative sample of the noninstitu-
tionalized, civilian U.S. population. The
sampling design oversamples non-
Hispanic blacks, Mexican Americans, in-
dividuals aged 60 years, and low-
income individuals to provide more
precise estimates for these speciﬁc
groups. We included 843 adults aged
20 years with valid measures of A1C
whowerenotpregnantandwhoreported
during an interview that a health care
professional had told them they have di-
abetes. The NHANES 1999–2002 under-
went institutional review board approval,
and written informed consent was ob-
tained from participants.
Measures
Sociodemographic characteristics and in-
formation on diabetes, health, and insur-
ance status were ascertained during
interviews.Age-groupswerebasedonap-
proximate quintiles of the analytic sam-
ple. Race/ethnicity was based on self-
identiﬁed race and Hispanic origin.
Income-to-poverty ratio was deﬁned as
the ratio of reported total family income
to the U.S. Census Bureau poverty
threshold. Diabetes medication was cat-
egorized as use of insulin (with or with-
out oral agents), use of oral agents only,
and no use.
Weight and height were measured
during a physical examination. BMI was
calculated as weight in kilograms divided
by the square of height in meters, and
weight status was categorized as under-
weight or normal weight, overweight,
obese, and severely obese with BMI cut
points of 25, 2529.9, 30–39.9, and
40 kg/m
2 (17). A1C was assessed by
boronateafﬁnityhigh-performanceliquid
chromatography using Primus CLC330
and Primus CLC 385 (Primus, Kansas
City, MO), and values were standardized
according to the method of the Diabetes
Control and Complications Trial (18,19),
yielding interassay coefﬁcients of varia-
tion of 3.0%.
Data analysis
The mean difference provides a measure
of disparity among different groups
within a population (20). We used the
mean difference to assess differences in
A1C threshold attainment by various
population groups within potential case
mixfactors.Foreachfactor,wecalculated
a mean difference to provide a summary
of the difference in proportion of people
with diabetes whose A1C was 7, 8,
and 9%. The mean difference is ex-
pressed in percentage points, across any
number,p,ofpopulationgroups.Theref-
erent for each threshold, rref, was selected
astheproportionexceedingthethreshold
among the overall population. These ref-
erent proportions are constant at a given
threshold and provide an intuitive stan-
dard from which to gauge differences
across groups. For each population
group, j, we calculated the proportion, rj,
exceeding the threshold, and the absolute
difference in that proportion from that of
the referent, rref. For each factor, the mean
difference was calculated using Equation 1.
Mean difference 

j1
p
rj  rref
p (1)
AllcalculationsweremadewithWes-
var(version5;Westat,Rockville,MD)us-
ing the 4-year examination sample
weights to account for the sample design
and nonresponse. Sampling variance was
calculated using the jackknife procedure,
appropriate for the complex, multistage
sample design (21), and 95% conﬁdence
limits were calculated by taking the natu-
ral logarithm of the mean difference, esti-
mating the standard error of the
transformed estimate, deriving conﬁ-
dence limits, and back-transforming the
conﬁdence limits via exponentiation.
Thistransformationresultsinasymmetric
conﬁdence limits but improves their va-
lidity (22). Student’s t tests were used to
test whether the differences between the
meandifferencesforthe7and8%thresh-
olds relative to the 9% threshold were
equal to 0.
RESULTS— The proportion of indi-
viduals whose A1C concentrations were
9, 8, and 7% are presented by var-
ious patient factors (Table 1). Frequency
distributions for each factor across the
overall population are provided for refer-
ence.Oftheoverall(unstratiﬁed)popula-
tion, 18.4% exceeded an A1C threshold
of9%,32.8%exceededanA1Cthreshold
of 8%, and 52.6% exceeded the ADA rec-
ommended target A1C of 7%. These pro-
portions provide the referent to which
subgroup threshold attainment is com-
pared. We ﬁrst present differences in
threshold attainment within factors and
then describe the effects of lowering the
A1C threshold on these differences.
Sociodemographic factors
For sociodemographic factors, important
differences existed across groups of age,
Bainbridge and Associates
DIABETES CARE, VOLUME 31, NUMBER 9, SEPTEMBER 2008 1755Table 1—Weighted frequency distribution of sociodemographic and health status factors, the proportion of each group exceeding three A1C
thresholds, and the mean difference across groups
Frequency
distribution
Proportion exceeding A1C threshold
9% 8% 7%
Overall population 100.0 18.4 32.8 52.6
Sociodemographic factors
Age
20–44 years 17.4 32.7 45.7 63.5
45–54 years 21.5 23.7 37.9 52.3
55–64 years 23.2 16.4 32.8 51.1
65–74 years 21.9 13.4 28.0 55.5
75 years 16.0 5.8 18.2 39.4
Mean difference 7.8 (4.4–13.9) 7.5 (3.7–15.1) 5.7 (2.9.–11.4)
Race/ethnicity
Non-Hispanic white 62.7 13.5 28.7 48.4
Non-Hispanic black 15.2 25.6 38.8 60.7
Mexican American 7.0 26.8 41.9 61.4
Other race, other Hispanic,
multiracial 15.2 27.8 39.2 57.8
Mean difference 7.4 (4.7–11.9) 6.4 (3.5,11.8) 6.6 (3.4–12.8)
Income-to-poverty ratio
0.8 10.7 32.4 40.2 58.0
0.8–2 36.1 14.9 29.5 51.1
2–4 30.6 17.5 34.5 51.2
4 22.6 15.1 27.1 51.1
Mean difference 5.4 (3.0–9.8) 4.5 (1.7–12.2) 2.5 (0.7–9.0)*
Insurance status
Uninsured 10.3 38.0 50.6 59.4
Private insurance 39.9 21.3 34.3 57.7
Public or government insurance 32.0 12.6 28.4 45.7
Both public and private insurance 17.9 11.5 25.9 49.3
Mean difference 8.8 (5.2–15.0) 7.6 (3.7–15.6) 5.6 (2.1–14.9)
Sex
Male 50.5 20.2 32.8 54.8
Female 49.5 16.7 32.7 50.3
Mean difference 1.8 (0.3–9.7) 0.0 (0.0–)† 2.2 (0.4–11.3)
Education
High school 36.4 21.4 34.7 54.8
High school Graduate 25.1 15.9 33.2 48.2
High school 38.6 17.3 30.6 53.3
Mean difference 2.2 (0.4–12.0) 1.5 (0.1–16.3) 2.4 (0.4–15.8)
Health status factors
Diabetes medication
Use of insulin 26.1 27.5 48.3 71.4
Use of oral agents only 55.5 16.0 29.2 52.0
No use of medications 18.4 13.0 21.5 27.7
Mean difference 5.7 (2.3–13.8) 10.1 (6.5–15.7)* 14.7 (10.8–20.1)‡
Diabetes duration
5 years 35.4 15.9 29.1 46.7
5t o10 years 20.8 25.5 39.8 58.4
10 to 15 years 13.5 22.3 39.8 62.8
15 to 20 years 7.5 23.6 38.2 62.6
20 years 22.8 12.5 27.0 48.4
Mean difference 4.9 (2.2–11.1) 5.8 (2.7–12.3) 7.2 (4.2–12.3)
Weight status
Underweight or normal weight 16.6 25.0 36.6 54.6
Overweight 31.5 19.1 28.6 50.8
Obese 38.1 17.0 38.8 54.9
Continued on facing page
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each of the A1C thresholds, whereas dif-
ferences across sex and education were
minor. The proportion with A1C 9%
declined steadily with increasing age,
such that 32.7% of those aged 20–44
years but only 13.4% of those aged
65–74 years and only 5.8% of those
aged 75 years surpassed the thresh-
old. The age gradient was not explained
by a shorter reported duration of diabetes
or a lower proportion of insulin use
among elderly individuals (data not
shown). In comparing each of the ﬁve
age-groups to the overall population, the
mean difference in the proportion with
A1C 9% was 7.8 (95% conﬁdence lim-
its 4.4–13.9) percentage points. The dif-
ference across race/ethnic groups was of a
magnitude similar to that for the age dif-
ference at this threshold. Among race/
ethnic groups, the proportion exceeding
any threshold was much lower for non-
Hispanic whites than for any minority
race/ethnic group. Almost one-third of
those most economically disadvantaged
(income-to-poverty ratio 0.8) had A1C
9%, but the proportions of individuals
in the other income-to-poverty ratio cat-
egories with A1C 9% were much lower
and ranged from 14.9 to 17.5%, resulting
in a mean difference of 5.4 (3.0–9.8) per-
centage points. Uninsured individuals
were more likely to have A1C 9% than
those with any insurance. The lower pro-
portionwithA1C9%amongthosewith
public insurance (and among those with
additional private insurance) appears to
beexplainedbytheMedicareeligibilityof
individuals aged 65 years, who have a
lower probability of poor control (data
not shown).
LoweringthethresholdtoA1C8or
7% did not signiﬁcantly affect most so-
ciodemographic disparities. The age gra-
dient persisted, and mean differences
across age and insurance status were
modestly reduced as the threshold was
lowered from 9t o7%. Mean differ-
ences across race/ethnic groups at the
lower thresholds remained substantial.
Lowering the threshold to A1C 8% did
not signiﬁcantly reduce the disparity
across income-to-poverty groups, but
lowering the threshold to A1C 7% re-
duced the mean difference to 2.5 (95%
conﬁdence limits 0.7–9.0) percentage
points, a signiﬁcant decline from the esti-
mate at 9% (P  0.05). Although our
analysis was framed in terms of the effect
on the mean difference across various
groups of lowering the threshold for poor
control,theresultsaresimilarifframedin
terms of raising the A1C threshold for
good control.
Health status factors
Among health status factors, the largest
difference at the 9% threshold was
found across diabetes medication catego-
ries. Compared with 18.4% overall, more
than one-quarter of individuals taking in-
sulin, 16% of those taking oral medica-
tions, and 13% of those using no
medications had concentrations above
this level, yielding a mean difference of
5.7 (95% conﬁdence limits 2.3–13.8)
percentage points. The relation of poor
glycemiccontrolbydiabetesdurationwas
U-shaped, as a lower proportion among
those with duration of diabetes 5 and at
least 20 years had A1C 9%; the mean
difference was 4.9 (2.2–11.1) percentage
points. The mean difference for weight
status was small at 3.3 (1.0–11.3) per-
centage points. Only 9.8% of individuals
who reported good or excellent health
Table 1—Continued
Frequency
distribution
Proportion exceeding A1C threshold
9% 8% 7%
Severely obese 13.9 13.8 22.5 53.7
Mean difference 3.3 (1.0–11.3) 6.1 (3.3–11.3) 1.8 (0.1–27.9)
Self-reported health
Excellent or very good 18.8 9.8 25.6 46.9
Good 36.6 20.0 31.4 49.7
Fair or poor 44.6 20.8 36.9 57.4
Mean difference 4.2 (2.0–9.1) 4.2 (1.3–14.0) 4.5 (1.4–14.3)
Number of prescription medications
0–1 19.4 25.6 39.5 55.5
2–3 27.4 17.0 31.0 52.2
4–6 29.7 16.3 28.6 49.0
7 23.5 16.7 34.3 54.7
Mean difference 3.1 (0.8–11.9) 3.5 (1.0–12.6) 2.2 (0.4–11.3)
Number of health care interactions
0–1 10.2 23.7 36.0 48.8
2–3 22.4 24.0 37.9 61.1
4–9 39.1 13.6 30.1 50.5
10–12 28.3 19.0 31.4 50.5
Mean difference 4.1 (1.5–11.1) 3.1 (0.4,22.0) 4.1 (1.5–11.7)
Hospitalization in last year
Yes 24.4 21.6 35.1 54.8
No 75.6 17.4 32.0 51.9
Mean difference 2.1 (0.1–34.5) 1.6 (0.1–25.3) 1.4 (0.0–†)
Data are % or mean difference (95% conﬁdence limits). Mean difference (expressed in percentage points) indicates absolute differences between the proportion of
the group and that of the total population exceeding the threshold. *P  0.05 for comparison to mean difference estimate for A1C 9%. †Calculation of upper
conﬁdence limit results in value above theoretical maximum. ‡P  0.001 for comparison to mean difference estimate for A1C 9%.
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porting good or fair to poor health had
concentrations above the threshold,
yielding a mean difference of 4.2 (2.0–
9.1) percentage points for self-reported
health. At A1C 9%, mean differences
across categories of number of prescrip-
tion medications and number of health
care interactions and hospitalization in
thelastyearweresmall,at3.1(0.8–11.9),
4.1 (1.5–11.1), and 2.1 (0.1–34.5) per-
centage points, respectively.
Lowering the threshold to A1C 8o r
7% had a large and signiﬁcant effect on
the mean difference across categories of di-
abetes medication. Compared with 32.8%
of the overall population, nearly half of
thosewhousedinsulinhadA1C8%,and
comparedwith52.6%overall,70%ofin-
sulin users had A1C 7%. Mean differ-
ences were 10.1 (95% conﬁdence limits
6.5–15.7) percentage points at A1C 8%
and 14.7 (10.8–20.1) percentage points at
A1C 7% (P  0.05 and P  0.001, re-
spectively, compared with A1C 9%). The
increase in the mean difference for diabetes
medication categories at sequentially lower
A1C thresholds reﬂects a differential in-
crease by type of medication in the propor-
tionexceedingthelowerthresholds(Fig.1).
When the threshold is lowered to A1C
8%, the proportion of insulin users ex-
ceeding the threshold increased by 20 per-
centage points (to include those with A1C
8–9%), compared with increases of 13
and 9 percentage points for those taking
oral agents and those not using medication,
respectively.Whenthethresholdislowered
toA1C7%,theincreaseintheproportion
above this threshold was 23 percentage
pointsfortheinsulinusersandthosetaking
oral agents (after including those with A1C
7–8%), but only 6 percentage points for
those using no medication. The mean dif-
ferences for the remaining health status fac-
tors were not signiﬁcantly affected by
lowering the A1C to 8o r7%.
In Table 2, patient factors were ranked
by mean differences at each A1C threshold.
Considering a mean difference of 5 per-
centage points as noteworthy, important
disparities were consistently observed
acrossallthreeA1Cthresholdsforage,race/
ethnicity, insurance, and diabetes medica-
tion, but their rank varied by threshold. At
A1C 9%, insurance, age, and race/
ethnicity contributed the greatest mean
differences in threshold attainment. At
lower thresholds, diabetes medication ex-
hibitedthegreatestdisparitywithmeandif-
ferences of 10 and almost 15 percentage
points. The average mean difference across
all factors was consistent (4.7–4.8) among
all thresholds.
CONCLUSIONS — This study dem-
onstrates the extent to which disparities
in glycemic control by patient subgroups
are mitigated or exacerbated by choice of
A1Cthresholdsof9,8,and7%.For
11 of the 13 factors examined, choice of
A1C threshold did not signiﬁcantly affect
the magnitude of population subgroup
Figure 1—Proportion of people with A1C 9, 8–9, and 7–8% by diabetes medication use.
Table 2—Sociodemographic and health status factors ranked by their mean difference according to A1C threshold
Rank 9% MD 8% MD 7% MD
1 Insurance status 8.8 Diabetes medication use 10.1 Diabetes medication use 14.7
2 Age-group 7.8 Insurance status 7.7 Years since diagnosis 7.2
3 Race/ethnicity 7.5 Age-group 7.5 Race/ethnicity 6.6
4 Diabetes medication use 5.7 Race/ethnicity 6.4 Age-group 5.8
5 Income-to-poverty ratio 5.4 Weight status 6.1 Insurance status 5.6
6 Years since diagnosis 4.9 Years since diagnosis 5.8 Self-reported health 4.5
7 Self-reported health 4.2 Income-to-poverty ratio 4.5 No. of health care interactions 4.1
8 No. of health care interactions 4.1 Self-reported health 4.2 Income-to-poverty ratio 2.5
9 Weight status 3.3 No. of prescription medications 3.5 Education 2.4
10 No. of prescription medications 3.1 No. of health care interactions 3.1 No. of prescription medications 2.3
11 Education 2.2 Hospitalization in last year 1.6 Sex 2.2
12 Hospitalization in last year 2.1 Education 1.5 Weight status 1.8
13 Sex 1.8 Sex 0.0 Hospitalization in last year 1.4
Average MD 4.7 4.8 4.7
Factors in bold are those for which the mean difference (MD) changed signiﬁcantly with the change in A1C threshold.
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ample, we observed pronounced race/
ethnicity differences in achievement of
glycemic control at all three thresholds,
a ﬁnding consistent with previous re-
search (23). We found no evidence,
however, that establishing a lower A1C
cutoff as a performance measure would
exacerbate this disparity or that select-
ing a less stringent threshold would ob-
viate the disparity.
Diabetes medication is the major pa-
tient factor for which differences in
threshold attainment would be exacer-
bated by lowering the current NDQIA
and NQF glycemic control performance
measure of A1C 9%. The importance of
diabetes treatment for good (A1C 7%)
glycemic control has been shown to be
independent of sociodemographic char-
acteristics, abdominal obesity, and health
care access and utilization (15). The mag-
nitude of this difference at the lower
thresholds has implications for pay for
performance quality improvement mod-
els being considered by the Centers for
Medicare & Medicaid Services and other
payers. Practices that include a greater
proportion of patients receiving insulin
may have proportionately more patients
exceeding A1C thresholds. A quality im-
provementsystemthatincludesanincen-
tive to achieve a performance measure for
glycemic control may not recognize ap-
propriate care given by physicians whose
practice includes a larger proportion of
people needing insulin for glycemic con-
trol, unless the system accounts for this
factor. Reporting performance measure
attainment speciﬁc to diabetes medica-
tion use, and insulin use in particular,
might be one means to account for this
difference in case mix, although imple-
menting this recommendation may not
currently be practical under most sys-
tems. As health systems move forward
withelectronicmedicalrecords,however,
capturing information on medication use
will be more feasible. Although auto-
mated review of electronic medical
recordsmaynotconsistentlycapturedata
on prescription medications (24), perfor-
mancemeasuresstratiﬁedbyprescription
medication may be a viable solution as
long as measures receive adequate ﬁeld
testing (25).
Differences across other patient
health factors examined (self-reported
health, number of prescription medica-
tions taken, and history of hospitaliza-
tion) were not greatly inﬂuenced by the
choice of glycemic control performance
measure threshold. Of the 13 factors
studied, only socioeconomic status (as
measuredbytheincome-to-povertyratio)
had a reduced disparity in threshold at-
tainment with a lower A1C threshold.
We observed a sizable difference in
threshold attainment by age, with im-
provedglycemiccontrolacrossincreasing
age-groups. The effect may be one of sur-
vivorship bias whereby life-threatening
complications are reduced among indi-
viduals with well-controlled diabetes or
may reﬂect milder disease with more
-cellfunctioninelderlyindividuals.The
poorer control in younger patients is om-
inous as they will have a longer duration
of diabetes and thus greater risk of com-
plications. Our ﬁndings also suggest that
the current NDQIA and NQF perfor-
mance measure of A1C 9% is unlikely
to drive major improvements in glycemic
control in the Medicare population as
only 13.4% of those aged 65–74 and
5.8% of those aged 75 had A1C 9%.
Ouranalysisofthesenationaldataof-
fers a response to a speciﬁc health policy
question being debated among groups
committed to establishing national health
care quality measures. Nonetheless, we
acknowledge several limitations. Recent
evidence suggests that differences in A1C
by race may reﬂect physiological differ-
encessuchasratesofglycationanderyth-
rocyte survival (26). Fair implementation
of threshold-based performance mea-
sures will depend on determining
whether small differences in A1C thresh-
old attainment truly indicate differences
in quality diabetes care after adjustment
for case mix. Diagnosed diabetes status
was assessed with a validated question
that nonetheless has a sensitivity of
	81% and a positive predictive value of
	89%(27).Anotherlimitationisthatour
analysis relied heavily on self-reported
case mix factors. The NHANES surveys
are designed to result in a representative
sample of the noninstitutionalized U.S.
population but may underrepresent non-
institutionalized persons with mental
health and substance abuse conditions, a
group shown to have poor glycemic con-
trol (28).
We conclude that implementing an
A1C performance measure to indicate
poor control that is more stringent than
the current measure of A1C 9% would
not increase disparities across most pa-
tient factors including age, race/ethnic
group, and socioeconomic status. To ac-
count for a case mix that includes more
insulin users, however, stakeholders con-
sidering the selection of a performance
measure threshold for glycemic control
that is 8% should consider reporting of
threshold attainment speciﬁc to diabetes
medication use. Stratiﬁed reporting
would allow more rigorous goals for gly-
cemic therapy in groups for whom a ben-
eﬁt has been established. In so doing,
lowering the A1C performance measure
thresholdmayadvancetheoverallquality
of diabetes care, without magnifying
overall differences among population
groups and without discouraging physi-
cian acceptance of insulin-requiring pa-
tients whose diabetes is more difﬁcult to
manage.
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